{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.92","value":"-1.9"}]}],"title":"Day 1: 1 hour"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.27","value":"-0.6"}]}],"title":"Day 2: pre-dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.94","value":"-2.1"}]}],"title":"Day 2: 1 hour"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.84","value":"1.3"}]}],"title":"Day 3: pre-dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.72","value":"-0.4"}]}],"title":"Day 3: 1 hour"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.20","value":"0.9"}]}],"title":"Day 4: pre-dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.65","value":"-1.7"}]}],"title":"Day 4: 1 hour"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.97","value":"-0.6"}]}],"title":"Day 5: pre-dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"6.62","value":"9.9"}]}],"title":"Day 5: 1 hour"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.59","value":"2.4"}]}],"title":"Day 6: pre-dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.78","value":"-1.0"}]}],"title":"Day 6: 1 hour"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"5.14","value":"-0.0"}]}],"title":"Day 7: pre-dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"5.92","value":"-0.6"}]}],"title":"Day 7: 1 hour"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"5.24","value":"1.5"}]}],"title":"Day 8"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"8.59","value":"3.4"}]}],"title":"Day 21"}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"description":"Triplicate ECG was measured in semi-supine position after 5 min rest. A single 12-lead ECG was measured by using ECG machine that automatically measures heart rate. Baseline is defined as the latest available assessment pre the first dose of study drug within each period in Part B. Change from Baseline was calculated as any visit post Baseline value minus Baseline value.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received GSK3039294 600 mg, capsules, orally, under fed condition, QD for 7 days in cohort 3.","id":"OG000","title":"Part B: Cohort 3- GSK3039294 600 mg QD"},{"description":"Participants were planned to receive repeat dose of GSK3039294 for 21 days in cohort 4a. The dose level was to be adjusted once during the 21 days. Cohort 4a was not initiated due to safety reasons during conduct of Part B (Cohort 3).","id":"OG001","title":"Part B: Cohort 4a- GSK3039294"},{"description":"Participants were planned to receive repeat dose of GSK3039294 for 21 days in cohort 4b. The dose level was to be adjusted once during the 21 days. Cohort 4b was not initiated due to safety reasons during conduct of Part B (Cohort 3).","id":"OG002","title":"Part B: Cohort 4b- GSK3039294"}],"paramType":"MEAN","populationDescription":"Safety population. Data was not collected as study was terminated, due to safety reasons during conduct of Part B (end of Cohort 3) whereas Cohort 4a and 4b were not recruited in Part B.","reportingStatus":"POSTED","timeFrame":"Cohort 3: Baseline (pre-dose), Day 1 (1 hour), Days 2, 3, 4, 5, 6, 7 (pre-dose and 1 hour), 8 and 21; Cohort 4: Up to Day 35","title":"Part B: Mean Change From Baseline in Heart Rate by 12-lead ECG","type":"PRIMARY","unitOfMeasure":"Beats per minute"}